Yang Shou-Bo, Gao Kai-Di, Jiang Tao, Cheng Shu-Jun, Li Wen-Bin
Department of Oncology, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
Beijing Rehabilitation Hospital of Capital Medical University, Beijing, China.
Oncotarget. 2017 Apr 7;8(34):57337-57344. doi: 10.18632/oncotarget.16924. eCollection 2017 Aug 22.
Bevacizumab, as antibodies, were applied to inhibit tumor angiogenesis by preventing activation of vascular endothelial growth factor receptor. We analyzed four clinical trials, including 607 patients, to investigate the efficacy and safety of bevacizumab when combined with chemotherapy for the treatment of glioblastomas. Results demonstrated that bevacizumab when combined with chemotherapy improved progression-free survival (HR = 0.66; 95% CI 0.56-0.78; < 0.00001) compared with bevacizumab or chemotherapy alone. Furthermore, overall survival showed insignificant difference between two arms (HR 0.99; 95% CI 0.8-1.21; = 0.92). However, we found that patients treated with bevacizumab-containing therapy reported increased objective response rate (OR 1.85, 95% CI 1.17-2.93; = 0.009), but more treatment-related adverse events (OR 1.75; 95% CI 1.09-2.83; = 0.02).
贝伐单抗作为抗体，通过阻止血管内皮生长因子受体的激活来抑制肿瘤血管生成。我们分析了四项临床试验，共607例患者，以研究贝伐单抗联合化疗治疗胶质母细胞瘤的疗效和安全性。结果表明，与单独使用贝伐单抗或化疗相比，贝伐单抗联合化疗可改善无进展生存期（HR = 0.66；95% CI 0.56 - 0.78；P < 0.00001）。此外，两组的总生存期无显著差异（HR 0.99；95% CI 0.8 - 1.21；P = 0.92）。然而，我们发现接受含贝伐单抗治疗的患者报告客观缓解率有所提高（OR 1.85，95% CI 1.17 - 2.93；P = 0.009），但治疗相关不良事件更多（OR 1.75；95% CI 1.09 - 2.83；P = 0.02）。
Zotero 插件